
A recent study evaluated the impact of semaglutide on coronary artery inflammation, measured via the pericoronary fat attenuation index (FAI), in 497 patients with type 2 diabetes mellitus (T2DM). Results showed that patients treated with semaglutide had lower FAI values in the left anterior descending (LAD) and left circumflex (LCX) arteries compared to those untreated. After propensity score matching (PSM) to adjust for confounders, lower FAI values were observed in all three major coronary arteries in the semaglutide group. Multivariate linear regression confirmed the independent association between semaglutide treatment and reduced coronary inflammation. These findings suggest that semaglutide may reduce coronary artery inflammation, contributing to its cardiovascular protective effects in T2DM patients.
Like
Save
Share